

Peter H Wiernik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7886341/publications.pdf>

Version: 2024-02-01

176
papers

7,139
citations

71102

41
h-index

64796

79
g-index

181
all docs

181
docs citations

181
times ranked

5362
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2. Journal of Investigative Medicine, 2021, 69, 888-892.	1.6	10
2	Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. British Journal of Haematology, 2021, 194, 309-318.	2.5	10
3	At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. British Journal of Haematology, 2020, 191, 37-43.	2.5	9
4	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biology of Blood and Marrow Transplantation, 2020, 26, 1137-1143.	2.0	13
5	Adult hypodiploid B-acute lymphoblastic leukaemia and stem cell transplantation. British Journal of Haematology, 2019, 186, 205-206.	2.5	0
6	Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature. Leukemia Research, 2018, 67, 39-44.	0.8	6
7	Androgen Therapy for Acute Myeloid and Hairy Cell Leukemia. Current Treatment Options in Oncology, 2018, 19, 4.	3.0	8
8	Diagnosis and Treatment of Hodgkin Lymphoma. , 2018, , 903-937.		0
9	Diagnosis and Treatment of Adult Acute Myeloid Leukemia Other than Acute Promyelocytic Leukemia. , 2018, , 375-407.		0
10	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 581-586.	2.0	5
11	Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Value of Interprofessional Health-Care Teams in Medication Prescribing and Medication Error Prevention. Journal of Clinical Pharmacology, 2018, 58, 843-848.	2.0	2
12	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 767-775.	2.0	41
13	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer, 2017, 123, 3141-3149.	4.1	65
14	Long-term (LT) disease-free survival (DFS) of melanoma (MM) and renal cell cancer (RCC) patients following high-dose interleukin-2 (HD IL2).. Journal of Clinical Oncology, 2017, 35, e21005-e21005.	1.6	5
15	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer, 2016, 122, 3005-3014.	4.1	45
16	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Journal of Clinical Oncology, 2016, 34, 1864-1871.	1.6	61
17	Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs, 2016, 25, 729-734.	4.1	62
18	Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. Journal of Clinical Oncology, 2016, 34, 3544-3553.	1.6	99

#	ARTICLE	IF	CITATIONS
19	New Cancers after Autotransplantations for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 738-745.	2.0	33
20	Familial Leukemias. <i>Current Treatment Options in Oncology</i> , 2015, 16, 8.	3.0	5
21	in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993. <i>Blood</i> , 2015, 126, 795-795.	1.4	0
22	Optimal Therapy for Adult Patients with Acute Myeloid Leukemia in First Complete Remission. <i>Current Treatment Options in Oncology</i> , 2014, 15, 171-186.	3.0	6
23	Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years. <i>Medical Oncology</i> , 2014, 31, 136.	2.5	2
24	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 951-959.	2.0	37
25	Diagnosis and Treatment of Hodgkin's Lymphoma. , 2013, , 985-1013.		0
26	All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129. <i>Leukemia Research</i> , 2013, 37, 795-801.	0.8	40
27	Diagnosis and Treatment of Adult Acute Myeloid Leukemia Other than Acute Promyelocytic Leukemia. , 2013, , 375-401.		1
28	Lenalidomide in lymphomas and chronic lymphocytic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 475-488.	1.8	8
29	Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493). <i>Leukemia and Lymphoma</i> , 2012, 53, 1137-1142.	1.3	4
30	Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). <i>Medical Oncology</i> , 2012, 29, 2095-2101.	2.5	19
31	Update: APOR. <i>Clinical and Translational Science</i> , 2011, 4, 399-399.	3.1	0
32	Detection of a new embryonic antigen (ESA-10) in the blood of patients with cancer: preliminary results in the United States. <i>Medical Oncology</i> , 2011, 28, 67-70.	2.5	0
33	Acute Lymphoblastic Leukemia of Adulthood: Progress or Not?. <i>Current Treatment Options in Oncology</i> , 2011, 12, 303-311.	3.0	1
34	Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129. <i>Blood</i> , 2011, 118, 83-83.	1.4	5
35	Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 242-8.	0.3	1
36	Phase II Study of Interleukin-4 in Indolent B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia: A Study of the Eastern Cooperative Oncology Group (E5Y92). <i>Journal of Immunotherapy</i> , 2010, 33, 1006-1009.	2.4	8

#	ARTICLE	IF	CITATIONS
37	Resolution of massive pleural effusion due to lymphoma with intrapleural interleukin-2. American Journal of Hematology, 2010, 85, 711-712.	4.1	5
38	FLT3 inhibitors for the treatment of acute myeloid leukemia. Clinical Advances in Hematology and Oncology, 2010, 8, 429-36, 444.	0.3	36
39	Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2009, 27, 5404-5409.	1.6	259
40	Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up. Leukemia and Lymphoma, 2009, 50, 1632-1641.	1.3	4
41	Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission. American Journal of Hematology, 2009, 84, 455-457.	4.1	2
42	Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. British Journal of Haematology, 2009, 145, 344-349.	2.5	247
43	Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs). Current Treatment Options in Oncology, 2009, 10, 1-15.	3.0	10
44	Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1134-1140.	2.0	27
45	Leukemic infiltration of the breast in acute lymphocytic leukemia (ALL). Hematology, 2008, 13, 101-106.	1.5	16
46	Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 4952-4957.	1.6	376
47	The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG).. Blood, 2008, 112, 1952-1952.	1.4	3
48	Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 2008, 112, 3314-3314.	1.4	1
49	Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG). Blood, 2008, 112, 49-49.	1.4	4
50	Serum CA125 and PSA concentrations in patients with lymphoma. Clinical Advances in Hematology and Oncology, 2008, 6, 527-31.	0.3	8
51	The influence of parental age and gender on anticipation in familial B-Cell malignancies. Medical Oncology, 2007, 24, 55-62.	2.5	9
52	Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma.. Blood, 2007, 110, 2560-2560.	1.4	2
53	Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma.. Blood, 2007, 110, 2564-2564.	1.4	1
54	Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.. Blood, 2007, 110, 2565-2565.	1.4	10

#	ARTICLE	IF	CITATIONS
55	Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkinâ€™s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.. Blood, 2007, 110, 2572-2572.	1.4	1
56	Treatment Type Determines Gene Expression Changes from Pretreatment (PTx) to Relapse (Rel) in Acute Promyelocytic Leukemia (APL).. Blood, 2007, 110, 3167-3167.	1.4	0
57	Plasma cell dyscrasias and leukemias. Update on Cancer Therapeutics, 2006, 1, 539-567.	0.4	0
58	Prolonged venous access for chemotherapy by means of the hickman catheter. Cancer, 2006, 52, 185-192.	4.1	109
59	Lenalidomide-Induced Warm Autoimmune Hemolytic Anemia. Journal of Clinical Oncology, 2006, 24, e59-e59.	1.6	26
60	Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkinâ€™s Lymphoma.. Blood, 2006, 108, 2482-2482.	1.4	11
61	Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkinâ€™s Lymphoma.. Blood, 2006, 108, 531-531.	1.4	14
62	Active Immunotherapy with FavldÂ® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).. Blood, 2006, 108, 691-691.	1.4	3
63	Common Gene Expression Changes in Matched Pretreatment and Relapse Samples from Eastern Cooperative Oncology Group Acute Promyelocytic Leukemia (APL) Patients Treated on the Chemotherapy (C) or All-Trans Retinoic Acid (ATRA)-Containing (A) Randomization Arms of Protocol E2491.. Blood, 2006, 108, 4311-4311.	1.4	0
64	Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias.. Blood, 2006, 108, 1836-1836.	1.4	0
65	KLHDC8B Is a Novel, Mitotically-Regulated Classical Hodgkinâ€™s Lymphoma Candidate Susceptibility Gene.. Blood, 2006, 108, 473-473.	1.4	4
66	Phenotypic Heterogeneity in Multiple Myeloma Families. Journal of Clinical Oncology, 2005, 23, 685-693.	1.6	52
67	Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: A study of the Eastern Cooperative Oncology Group (E1993). Leukemia and Lymphoma, 2005, 46, 377-385.	1.3	8
68	Plasma cell dyscrasias and leukemias. Cancer Chemotherapy and Biological Response Modifiers, 2005, , 343-389.	0.5	1
69	Plasma cell dyscrasias and leukemias. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 343-89.	0.5	1
70	The association between breast cancer and lymphoma. Clinical Advances in Hematology and Oncology, 2005, 3, 695-6.	0.3	7
71	Clonal Isolation of Different Strains of Mouse Mammary Tumor Virus-Like DNA Sequences from Both the Breast Tumors and Non-Hodgkinâ€™s Lymphomas of Individual Patients Diagnosed with Both Malignancies. Clinical Cancer Research, 2004, 10, 5656-5664.	7.0	50
72	Cardiac monitoring of patients receiving arsenic trioxide therapy. British Journal of Haematology, 2004, 124, 610-617.	2.5	46

#	ARTICLE	IF	CITATIONS
73	Second neoplasms in patients with chronic lymphocytic leukemia. Current Treatment Options in Oncology, 2004, 5, 215-223.	3.0	53
74	Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer, 2004, 101, 1414-1419.	4.1	13
75	Id/KLH Vaccine (Favldâ,ç) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).. Blood, 2004, 104, 587-587.	1.4	6
76	Mutation of Cellular Retinoic Acid-Binding Protein-II (Crabp-II) Does Not Account for Resistance to All-Trans Retinoic Acid (ATRA) in Relapse Acute Promyelocytic Leukemia (APL).. Blood, 2004, 104, 2081-2081.	1.4	4
77	Metastatic Choriocarcinoma in a Middle-Aged Man Presenting as a Right Thigh Mass with Venous Thrombosis: A Case Report. Medical Oncology, 2003, 20, 189-194.	2.5	4
78	Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: Case report and literature review. American Journal of Hematology, 2003, 72, 267-273.	4.1	26
79	A Randomized Trial of Induction Therapy (Daunorubicin, Vincristine, Prednisone versus Daunorubicin,) Tj ETQq1 1 0.784314 rgBT /Overlo Long-term Follow-up: An Eastern Cooperative Oncology Group Study (E3486). Leukemia and Lymphoma, 2003, 44, 1515-1521.	1.3	3
80	Plasma cell myeloma and leukemia. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 365-397.	0.5	0
81	All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood, 2002, 100, 4298-4302.	1.4	427
82	Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood, 2001, 97, 1514-1516.	1.4	180
83	Anticipation in familial chronic lymphocytic leukaemia. British Journal of Haematology, 2001, 113, 407-414.	2.5	58
84	Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. American Journal of Hematology, 2001, 66, 189-196.	4.1	34
85	Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Investigational New Drugs, 2001, 19, 89-92.	2.6	28
86	Hairy cell leukemia in first cousins and review of the literature. European Journal of Haematology, 2001, 67, 185-188.	2.2	22
87	Bleomycin, Lomustine, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BLEO-CCVPP) in Patients with Hodgkin's Disease who Relapsed after Radiotherapy Alone: a Long-Term Foliow-Up Study of the Eastern Cooperative Oncology Group (E3481). Leukemia and Lymphoma, 2001, 40, 357-363.	1.3	2
88	20thâ€Century Advances in Drug Therapy in Oncologyâ€™Part I. Journal of Clinical Pharmacology, 2000, 40, 1007-1024.	2.0	22
89	Age of onset evidence for anticipation in familial nonâ€Hodgkin's lymphoma. British Journal of Haematology, 2000, 108, 72-79.	2.5	46
90	Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar). Blood, 1999, 93, 787-795.	1.4	141

#	ARTICLE	IF	CITATIONS
91	Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Medical Oncology, 1999, 16, 58-64.	2.5	84
92	Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia. , 1999, 85, 358-367.		35
93	The War on Healthcare Professionals and Healthcare Delivery. Cancer Investigation, 1999, 17, 164-169.	1.3	0
94	Pseudoautosomal Linkage of Hodgkin Disease. American Journal of Human Genetics, 1999, 65, 1413-1422.	6.2	58
95	Circulating haemopoietic progenitor cells in primary and secondary myelofibrosis: relation to collagen and reticulin fibrosis. European Journal of Haematology, 1999, 62, 155-159.	2.2	14
96	The War on Healthcare Professionals and Healthcare Delivery. Cancer Investigation, 1999, 17, 164-169.	1.3	0
97	Recombinant interferon- γ therapy in patients with follicular lymphoma. , 1998, 82, 1821-1830.		17
98	Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Medical Oncology and Tumor Pharmacotherapy, 1998, 15, 50-57.	1.1	62
99	Anticipation in familial plasma cell dyscrasias. British Journal of Haematology, 1998, 103, 696-703.	2.5	36
100	Familial Hairy Cell Leukemia. Leukemia and Lymphoma, 1998, 29, 193-197.	1.3	15
101	Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission. New England Journal of Medicine, 1998, 339, 1649-1656.	27.0	569
102	Familial Erythroleukemia: A Distinct Clinical and Genetic Type of Familial Leukemias. Leukemia and Lymphoma, 1998, 30, 395-401.	1.3	12
103	Methylguazone, Vindesine and Cisplatin for the Treatment of Patients with Relapsed or Refractory Malignant Lymphoma: An Eastern Cooperative Oncology Group Study (PA482). Leukemia and Lymphoma, 1998, 30, 619-624.	1.3	2
104	All- <i>trans</i> -Retinoic Acid in Acute Promyelocytic Leukemia. New England Journal of Medicine, 1997, 337, 1021-1028.	27.0	1,006
105	Phase II trial of merbarone in patients with malignant brain tumors. Medical Oncology, 1997, 14, 159-162.	2.5	10
106	Therapeutic effect of cyclosporine A in thrombocytopenia after myeloablative chemotherapy in acute myeloid leukaemia. Medical Oncology, 1997, 14, 43-46.	2.5	4
107	Long-term survival in acute myeloid leukemia. Cancer, 1997, 80, 2205-2209.	4.1	70
108	Acute leukaemia following renal transplantation. Medical Oncology, 1996, 13, 9-13.	2.5	14

#	ARTICLE	IF	CITATIONS
109	Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. <i>Medical Oncology</i> , 1996, 13, 111-117.	2.5	35
110	Phase II clinical trial with 5-fluorouracil, recombinant interferon- β -2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. <i>Cancer</i> , 1996, 78, 30-34.	4.1	21
111	Occurrence of Myeloma in a Chronic Lymphocytic Leukemia Patient After Response to Differentiation Therapy with Interleukin-4. <i>Leukemia and Lymphoma</i> , 1996, 23, 617-619.	1.3	20
112	Treatment of adult patients with acute lymphocytic leukemia in relapse. <i>Leukemia and Lymphoma</i> , 1996, 20, 317-319.	1.3	9
113	Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. <i>Cancer</i> , 1995, 75, 2782-2784.	4.1	3
114	Acute promyelocytic leukemia and pregnancy. A case report. <i>Cancer</i> , 1995, 76, 2237-2241.	4.1	28
115	Unique Dermatological Complication of rhM-CSF Treatment. <i>Leukemia and Lymphoma</i> , 1994, 15, 347-349.	1.3	5
116	Objective Response of Multiple Myeloma to Cyclosporin A. <i>Leukemia and Lymphoma</i> , 1994, 16, 167-170.	1.3	5
117	Low grade malignant hemangioendothelioma of bone: A disease potentially curable with radiotherapy. <i>Medical and Pediatric Oncology</i> , 1994, 23, 144-148.	1.0	14
118	Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. <i>American Journal of Hematology</i> , 1994, 47, 41-44.	4.1	17
119	Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 266-269.	2.3	38
120	Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 266-269.	2.3	5
121	Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. <i>Cancer</i> , 1993, 71, 1726-1730.	4.1	31
122	<i>Clostridium cadaveris</i> bacteremia in the immunocompromised host. <i>Medical and Pediatric Oncology</i> , 1993, 21, 70-72.	1.0	11
123	Retinoids in Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 868-888.	2.0	65
124	Cerebral infection complicating systemic aspergillosis in acute leukemia: clinical and radiographic presentation. <i>Journal of Neuro-Oncology</i> , 1992, 13, 91-100.	2.9	14
125	A phase II trial of CI-921 in advanced malignancies. <i>Investigational New Drugs</i> , 1992, 10, 309-312.	2.6	20
126	Association of thyroid disease with acute leukemia. <i>American Journal of Hematology</i> , 1992, 39, 102-107.	4.1	28

#	ARTICLE	IF	CITATIONS
127	Monosomy 7 in multilineage and acute lymphoblastic leukaemia. British Journal of Haematology, 1991, 79, 152-155.	2.5	20
128	Complete remission in refractory anaplastic adult wilms' tumor treated with cisplatin and etoposide. Cancer, 1991, 67, 956-959.	4.1	18
129	13-cis-retinoic acid in the treatment of elderly patients with acute myeloid leukemia. A phase II pilot study of the eastern cooperative oncology group. Cancer, 1991, 67, 1484-1486.	4.1	14
130	Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. Cancer, 1991, 68, 1538-1544.	4.1	56
131	Disseminated aspergillosis after fungemia in a patient with extragonadal germ cell tumor undergoing autologous bone marrow transplantation. Cancer, 1991, 68, 1842-1844.	4.1	6
132	Effect of histocompatibility factors on pulmonary retention of indium-111-labeled granulocytes. American Journal of Hematology, 1990, 33, 238-243.	4.1	12
133	Inflammatory Pseudotumor of Spleen. Cancer, 1990, 66, 597-600.	4.1	67
134	Disseminated strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with acquired immunodeficiency syndrome and Burkitts lymphoma. Cancer, 1990, 66, 2417-2420.	4.1	52
135	SMALL BOWEL OBSTRUCTION AS A LATE COMPLICATION OF THE TREATMENT OF HODGKIN'S DISEASE. ANZ Journal of Surgery, 1990, 60, 585-588.	0.7	6
136	Granulocyte transfusion therapy and amphotericin B: Adverse reactions?. American Journal of Hematology, 1989, 31, 102-108.	4.1	50
137	Adenocarcinoma arising in vulvar breast tissue. Cancer, 1988, 62, 2234-2238.	4.1	41
138	Phase I and II Agents in Cancer Therapy: Two Cisplatin Analogues and High-Dose Cisplatin in Hypertonic Saline or With Thiosulfate Protection. Journal of Clinical Pharmacology, 1987, 27, 357-365.	2.0	12
139	Phase I and II Agents in Cancer Therapy: I. Anthracyclines and Related Compounds. Journal of Clinical Pharmacology, 1986, 26, 491-509.	2.0	36
140	Porphyria cutanea tarda in a patient with acute leukemia. American Journal of Hematology, 1986, 23, 69-75.	4.1	6
141	Plasmacytoid blast crisis in B-cell chronic lymphocytic leukemia: Effect of estradiol on growth and differentiation in vitro. Leukemia Research, 1985, 9, 19-29.	0.8	11
142	Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. Cancer, 1984, 53, 557-562.	4.1	46
143	Doxorubicin, cyclophosphamide, and whole body hyperthermia for treatment of advanced soft tissue sarcoma. Cancer, 1984, 53, 2585-2591.	4.1	42
144	Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma. Cancer Chemotherapy and Pharmacology, 1983, 10, 104-108.	2.3	19

#	ARTICLE	IF	CITATIONS
145	Ineffectiveness of chemotherapy in patients with metastatic ependymoma of the cauda equina. Journal of Surgical Oncology, 1983, 22, 33-36.	1.7	12
146	Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide. Clinical Pharmacology and Therapeutics, 1982, 32, 122-128.	4.7	27
147	Lung cancer as a complication of prolonged survival in patients with lymphoma. Medical and Pediatric Oncology, 1982, 10, 331-338.	1.0	21
148	Hydrocele following treatment for Hodgkin's disease. Cancer, 1982, 50, 305-307.	4.1	7
149	Possible pulmonary toxicity secondary to vinblastine. Cancer, 1982, 50, 2771-2774.	4.1	38
150	Initial Observations on the Effects of Δ^9 -Tetrahydrocannabinol on the Plasma Pharmacokinetics of Cyclophosphamide and Doxorubicin. Journal of Clinical Pharmacology, 1981, 21, 90S-98S.	2.0	7
151	Treatment of advanced untreated Hodgkin's disease with SCAB as an alternative to MOPP. Cancer, 1981, 47, 224-228.	4.1	19
152	Hypertrophic pulmonary osteoarthropathy and metastases from a malignant fibrous histiocytoma. Cancer, 1980, 45, 595-598.	4.1	8
153	Chemotherapy versus chemoimmunotherapy for small-cell undifferentiated carcinoma of the lung. Cancer, 1980, 46, 2543-2549.	4.1	41
154	Acute promyelocytic leukemia clinical management of 15 patients. American Journal of Hematology, 1980, 8, 347-359.	4.1	63
155	Granulocyte Transfusions: Evaluation of Factors Influencing Results and a Comparison of Filtration and Intermittent Centrifugation Leukapheresis. British Journal of Haematology, 1978, 38, 121-129.	2.5	36
156	Frozen Autologous Platelet Transfusion for Patients with Leukemia. New England Journal of Medicine, 1978, 299, 7-12.	27.0	120
157	Adriamycin therapy in advanced mycosis fungoides. Cancer, 1977, 39, 1967-1970.	4.1	22
158	The therapeutic implications of splenic involvement in stage IIIA Hodgkin's disease. Cancer, 1977, 39, 2158-2165.	4.1	52
159	False positive lymphography in Hodgkin's disease: A histologic-lymphadenographic correlation. Medical and Pediatric Oncology, 1977, 3, 253-259.	1.0	0
160	Combination chemotherapy of adult acute lymphocytic leukemia. Clinical Pharmacology and Therapeutics, 1976, 19, 240-245.	4.7	20
161	Combination chemotherapy with adriamycin and streptozotocin; I. Clinical results in patients with advanced sarcoma. Clinical Pharmacology and Therapeutics, 1976, 20, 605-610.	4.7	16
162	Clinical Experience with Transfusion of Cryopreserved Platelets. British Journal of Haematology, 1976, 34, 377-385.	2.5	59

#	ARTICLE	IF	CITATIONS
163	A phase II study of intravenously-administered methyl CCNU in the treatment of advanced sarcomas. Cancer, 1976, 37, 615-619.	4.1	9
164	Cost analysis of leukemia treatment. A problem-oriented approach. Cancer, 1976, 37, 646-652.	4.1	12
165	Antibody response in patients with acute nonlymphocytic leukemia. Cancer, 1976, 37, 2177-2182.	4.1	85
166	A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia. Cancer, 1976, 38, 36-41.	4.1	52
167	Intrathecal n, nâ€², nâ€²-triethylenethiophosphoramide [thio-tepa (NSC 6396)] in the treatment of malignant meningeal disease.Phase III study. Cancer, 1976, 38, 1471-1475.	4.1	73
168	Methotrexate pneumonitis induced by intrathecal methotrexate therapy.A case report with pharmacokinetic data. Cancer, 1976, 38, 1529-1534.	4.1	57
169	Reverse Transcriptase in Leukocytes of Leukemic Patients in Remission. New England Journal of Medicine, 1976, 294, 75-80.	27.0	41
170	The Significance of Abnormal Circulating Cells in Patients with Hodgkin's Disease. British Journal of Haematology, 1975, 31, 177-183.	2.5	8
171	A combined modality approach to the treatment of Hodgkin's disease.Preliminary results of a prospectively randomized clinical trial. Cancer, 1975, 35, 1055-1065.	4.1	55
172	Role of ⁶⁷ gallium citrate scanning in the management of non-hodgkin's lymphoma. Cancer, 1975, 36, 1690-1701.	4.1	40
173	Primary mediastinal choriocarcinoma in the male. Cancer, 1974, 33, 1196-1203.	4.1	59
174	Serum alpha fetoprotein concentration and tumor growth dissociation in a patient with ovarian teratocarcinoma. Cancer, 1973, 31, 835-839.	4.1	51
175	FACTORS EFFECTING REMISSION AND SURVIVAL IN ADULT ACUTE NONLYMPHOCYTIC LEUKEMIA (ANLL). Medicine (United States), 1970, 49, 505.	1.0	88
176	Pulmonary embolus in acute myelocytic leukemia. Cancer, 1969, 24, 581-584.	4.1	17